相关实验视频

Updated: Feb 25, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

在异常性肺纤维化上解码他莫西芬:整合网络毒理学和多omics

Yihan Sun^1,2, Ziyi Lu^1,3, Wenyao Yu⁴

¹Wenzhou Medical University, Wenzhou, Zhejiang, China.

International journal of surgery (London, England)

|February 24, 2026

概括

塔莫西芬暴露会通过miR-432-3p介导的EGFR通路引起肺纤维化,将其确定为肺毒性物质. 这项研究强调了环境风险,并建议EGFR作为异常性肺纤维化 (IPF) 的诊断生物标志物.

科学领域:

毒理学毒理学毒理学
肺部病理学肺部病理学
基因组学就是基因组学.
药理学药理学是指药理学的学科.

背景情况:

异形性肺纤维化 (IPF) 是一种致命的肺病,治疗选择很少.
用于治疗乳腺癌的塔莫西芬会给环境带来风险,其在IPF中的作用尚不清楚.

研究的目的:

调查他莫西芬和IPF之间的因果关系.
阐明泰莫西芬诱导的肺纤维化背后的分子机制.
为了确定潜在的诊断生物标志物,以确定与他莫西芬相关的肺毒性.

主要方法:

综合计算毒理学,药监监测 (FAERS) 和孟德尔随机化 (MR) 来评估他莫西芬与IPF的联系.
网络毒理学和多组学分析 (转录组学,scRNA-seq) 以确定关键基因和细胞通路.
在体内小鼠模型和分子对接以验证他莫西芬-miRNA-EGFR轴.

主要成果:

塔莫西芬具有较高的呼吸道毒性潜力,MR证实了因果性IPF风险.
发现了一种新的tamoksifen-miRNA-EGFR轴,涉及miR-432-3p上调和EGFR失调 (p-EGFR升高).
在体内研究证实,他莫西芬通过这个轴促进肺纤维化,p-EGFR和miR-432-3p的升高.

结论:

塔莫西芬通过miR-432-3p介导的EGFR抑制诱导IPF,将其归类为肺毒性物质.
EGFR被确定为因他莫西芬诱导的肺损伤的潜在诊断生物标志物.
这项研究强调了与他莫西芬暴露相关的环境和临床风险.

关键词:

破坏内分泌的化学物质破坏内分泌的化学物质异形性肺纤维化异形性肺纤维化多种主题的多种主题.网络毒理学网络毒理学泰莫西芬 (Tamoxifen) 是一种

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...